激动剂-话题@MedSci

#激动剂#

173篇内容 | 3658人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1627846, encodeId=13d8162e8462d, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=PLoS One：使用促性腺激素释放激素激动剂治疗的前列腺癌患者发生痴呆和帕金森病的风险研究, objectType=article, longId=205538, objectId=306b20553805, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306b20553805, replyNumber=0, likeNumber=69, createdTime=2021-01-11, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306b20553805, moduleTitle=PLoS One：使用促性腺激素释放激素激动剂治疗的前列腺癌患者发生痴呆和帕金森病的风险研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306b20553805)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627845, encodeId=ce7e162e84575, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=血管紧张素II 2型受体激动剂C21在COVID-19研究中显示出希望, objectType=article, longId=204986, objectId=852b204986f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=852b204986f9, replyNumber=0, likeNumber=152, createdTime=2020-12-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=852b204986f9, moduleTitle=血管紧张素II 2型受体激动剂C21在COVID-19研究中显示出希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=852b204986f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627844, encodeId=f7ff162e844c2, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Acta Obstet Gynecol Scand：腹腔镜子宫肌瘤切除术前使用醋酸乌利司他VS促性腺激素释放激素激动剂预处理的效果, objectType=article, longId=204641, objectId=841120464119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=841120464119, replyNumber=0, likeNumber=56, createdTime=2020-12-19, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=841120464119, moduleTitle=Acta Obstet Gynecol Scand：腹腔镜子宫肌瘤切除术前使用醋酸乌利司他VS促性腺激素释放激素激动剂预处理的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=841120464119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627843, encodeId=cc67162e84397, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetologia：在饮食诱导肥胖的小鼠中，用羟甲基戊二羟肾上腺素受体激动剂刺激骨骼肌中葡萄糖的摄取，改善葡萄糖稳态、胰岛素抵抗和肝脂肪变性, objectType=article, longId=203953, objectId=8cb02039536a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8cb02039536a, replyNumber=0, likeNumber=30, createdTime=2020-12-02, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8cb02039536a, moduleTitle=Diabetologia：在饮食诱导肥胖的小鼠中，用羟甲基戊二羟肾上腺素受体激动剂刺激骨骼肌中葡萄糖的摄取，改善葡萄糖稳态、胰岛素抵抗和肝脂肪变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8cb02039536a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627842, encodeId=0e00162e8425e, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Aging Cell：PPARγ激动剂罗西格列酮可助力健康长寿, objectType=article, longId=203665, objectId=5f152036652b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f152036652b, replyNumber=0, likeNumber=67, createdTime=2020-11-25, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f152036652b, moduleTitle=Aging Cell：PPARγ激动剂罗西格列酮可助力健康长寿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f152036652b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627841, encodeId=cf45162e84154, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Nat Commun：突破！中山大学蒋先兴团队开发了脂联素的激动剂，对于治疗肝纤维化有重要应用前景, objectType=article, longId=203610, objectId=c91220361065, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c91220361065, replyNumber=0, likeNumber=58, createdTime=2020-11-23, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c91220361065, moduleTitle=Nat Commun：突破！中山大学蒋先兴团队开发了脂联素的激动剂，对于治疗肝纤维化有重要应用前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c91220361065)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627840, encodeId=64f0162e84042, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, objectType=article, longId=203520, objectId=4ff9203520a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff9203520a1, replyNumber=0, likeNumber=64, createdTime=2020-11-20, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff9203520a1, moduleTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff9203520a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627839, encodeId=b155162e83945, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, objectType=article, longId=202037, objectId=84d120203ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84d120203ed5, replyNumber=0, likeNumber=55, createdTime=2020-10-14, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84d120203ed5, moduleTitle=FXR激动剂ASC42治疗NASH：美国FDA已批准IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84d120203ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627838, encodeId=3775162e8389e, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Ann Clin Transl Neurol：CXCR4受体激动剂可在坐骨神经损伤后刺激轴突的再生, objectType=article, longId=201537, objectId=e77820153ec4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77820153ec4, replyNumber=0, likeNumber=65, createdTime=2020-10-04, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77820153ec4, moduleTitle=Ann Clin Transl Neurol：CXCR4受体激动剂可在坐骨神经损伤后刺激轴突的再生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e77820153ec4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627837, encodeId=efc2162e837c3, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=特发性肺纤维化的治疗突破！AT2R激动剂VP01或具强大作用, objectType=article, longId=201250, objectId=9121201250c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9121201250c6, replyNumber=0, likeNumber=64, createdTime=2020-09-28, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9121201250c6, moduleTitle=特发性肺纤维化的治疗突破！AT2R激动剂VP01或具强大作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9121201250c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627836, encodeId=f244162e83673, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Br J Cancer：新型PPARγ激动剂CB11：非小细胞肺癌的潜在治疗药物, objectType=article, longId=201141, objectId=2fc5201141d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc5201141d5, replyNumber=0, likeNumber=78, createdTime=2020-09-25, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc5201141d5, moduleTitle=Br J Cancer：新型PPARγ激动剂CB11：非小细胞肺癌的潜在治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc5201141d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627835, encodeId=ceec162e835f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Acta Neuropathologica: KBTBD6/7-DRD2轴调控垂体腺瘤对多巴胺激动剂治疗的敏感性 , objectType=article, longId=200403, objectId=69f82004032a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69f82004032a, replyNumber=0, likeNumber=72, createdTime=2020-09-09, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69f82004032a, moduleTitle=Acta Neuropathologica: KBTBD6/7-DRD2轴调控垂体腺瘤对多巴胺激动剂治疗的敏感性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69f82004032a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627834, encodeId=2b53162e83406, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=雌激素受体激动剂TTC-352，一种有治疗潜力的抗乳腺癌药物, objectType=article, longId=200041, objectId=58b020004184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58b020004184, replyNumber=0, likeNumber=91, createdTime=2020-08-31, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b020004184, moduleTitle=雌激素受体激动剂TTC-352，一种有治疗潜力的抗乳腺癌药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b020004184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627833, encodeId=7816162e833d8, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Prostate Cancer P D：前列腺癌患者的心脏标记和接受促性腺激素释放激素激动剂与拮抗剂患者的心血管疾病研究, objectType=article, longId=199759, objectId=d24f199e5947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d24f199e5947, replyNumber=0, likeNumber=72, createdTime=2020-08-22, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d24f199e5947, moduleTitle=Prostate Cancer P D：前列腺癌患者的心脏标记和接受促性腺激素释放激素激动剂与拮抗剂患者的心血管疾病研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d24f199e5947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627832, encodeId=8da7162e8323a, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Stroke：胰岛素样肽-1受体激动剂可降低T2D患者非致命性卒中的发病风险, objectType=article, longId=199746, objectId=66ac199e4635, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66ac199e4635, replyNumber=0, likeNumber=90, createdTime=2020-08-22, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66ac199e4635, moduleTitle=Stroke：胰岛素样肽-1受体激动剂可降低T2D患者非致命性卒中的发病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66ac199e4635)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627831, encodeId=092f162e83138, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=J Allergy Clin Immunol：哮喘和过敏性鼻炎患者中对TLR7/8激动剂的鼻粘膜干扰素和CCL13反应增加, objectType=article, longId=199556, objectId=2e4f199556ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e4f199556ba, replyNumber=0, likeNumber=66, createdTime=2020-08-18, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e4f199556ba, moduleTitle=J Allergy Clin Immunol：哮喘和过敏性鼻炎患者中对TLR7/8激动剂的鼻粘膜干扰素和CCL13反应增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e4f199556ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627830, encodeId=c6a3162e83051, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=J Thromb Haemost：苯二氮卓受体激动剂与静脉血栓栓塞风险, objectType=article, longId=198915, objectId=5a74198915a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a74198915a1, replyNumber=0, likeNumber=70, createdTime=2020-08-08, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a74198915a1, moduleTitle=J Thromb Haemost：苯二氮卓受体激动剂与静脉血栓栓塞风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a74198915a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627829, encodeId=4c13162e829ef, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Sci Rep：抗毒蕈碱药物和β-3肾上腺受体激动剂治疗膀胱过度活跃中效果真实世界研究, objectType=article, longId=198659, objectId=6edc19865924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6edc19865924, replyNumber=0, likeNumber=122, createdTime=2020-08-05, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6edc19865924, moduleTitle=Sci Rep：抗毒蕈碱药物和β-3肾上腺受体激动剂治疗膀胱过度活跃中效果真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6edc19865924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627828, encodeId=ae09162e8289d, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖, objectType=article, longId=198242, objectId=909a19824200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909a19824200, replyNumber=0, likeNumber=61, createdTime=2020-07-30, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909a19824200, moduleTitle=Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909a19824200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1627827, encodeId=20c8162e827de, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, objectTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, objectType=article, longId=197999, objectId=2c2219e999bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c2219e999bb, replyNumber=0, likeNumber=65, createdTime=2020-07-26, rootId=0, userName=medscijoin, userId=95bc21134754, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c2219e999bb, moduleTitle=双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c2219e999bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激动剂

2020-05-29

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

PLoS One：使用促性腺激素释放激素激动剂治疗的前列腺癌患者发生痴呆和帕金森病的风险研究

2021-01-11

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

血管紧张素II 2型受体激动剂C21在COVID-19研究中显示出希望

2020-12-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Acta Obstet Gynecol Scand：腹腔镜子宫肌瘤切除术前使用醋酸乌利司他VS促性腺激素释放激素激动剂预处理的效果

2020-12-19

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetologia：在饮食诱导肥胖的小鼠中，用羟甲基戊二羟肾上腺素受体激动剂刺激骨骼肌中葡萄糖的摄取，改善葡萄糖稳态、胰岛素抵抗和肝脂肪变性

2020-12-02

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Aging Cell：PPARγ激动剂罗西格列酮可助力健康长寿

2020-11-25

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Nat Commun：突破！中山大学蒋先兴团队开发了脂联素的激动剂，对于治疗肝纤维化有重要应用前景

2020-11-23

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显

2020-11-20

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

FXR激动剂ASC42治疗NASH：美国FDA已批准IND

2020-10-14

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Ann Clin Transl Neurol：CXCR4受体激动剂可在坐骨神经损伤后刺激轴突的再生

2020-10-04

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

特发性肺纤维化的治疗突破！AT2R激动剂VP01或具强大作用

2020-09-28

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Br J Cancer：新型PPARγ激动剂CB11：非小细胞肺癌的潜在治疗药物

2020-09-25

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Acta Neuropathologica: KBTBD6/7-DRD2轴调控垂体腺瘤对多巴胺激动剂治疗的敏感性

2020-09-09

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

雌激素受体激动剂TTC-352，一种有治疗潜力的抗乳腺癌药物

2020-08-31

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Prostate Cancer P D：前列腺癌患者的心脏标记和接受促性腺激素释放激素激动剂与拮抗剂患者的心血管疾病研究

2020-08-22

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Stroke：胰岛素样肽-1受体激动剂可降低T2D患者非致命性卒中的发病风险

2020-08-22

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

J Allergy Clin Immunol：哮喘和过敏性鼻炎患者中对TLR7/8激动剂的鼻粘膜干扰素和CCL13反应增加

2020-08-18

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

J Thromb Haemost：苯二氮卓受体激动剂与静脉血栓栓塞风险

2020-08-08

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Sci Rep：抗毒蕈碱药物和β-3肾上腺受体激动剂治疗膀胱过度活跃中效果真实世界研究

2020-08-05

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖

2020-07-30

medscijoin (审核中...)

前往app查看评论内容

#激动剂#

双重PPAR激动剂治疗非酒精性脂肪性肝炎：III期临床宣布失败

2020-07-26

科室
- - 订阅+
  - 更多科室
工具
服务